Literature DB >> 31322481

Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant TERT promoter methylation, but not hot-spot mutations.

Omid Fotouhi1, Mehran Ghaderi1, Na Wang1,2, Jan Zedenius3,4, Magnus Kjellman3,4, Dawei Xu5, C Christofer Juhlin1,2, Catharina Larsson1,2.   

Abstract

Telomere maintenance is a critical requirement for enabling replicative immortality and tumour development. Here, telomerase expression and activity, telomere length (TL) and potential regulatory factors that can underlie telomerase machinery alterations in small intestinal neuroendocrine tumours (SI-NETs) were analyzed. Telomerase activity assessed by TRAP assay was increased in SI-NETs compared to normal ileum (P < 0.001). The telomerase reverse transcriptase gene (TERT) was over-expressed in SI-NETs vs. normal ileal samples (P = 0.01). Furthermore, relative TL assessed by qPCR was found shorter in tumours compared with normal ileum (P = 0.02) and in distant metastasis samples compared to primary tumours and local metastases (P= 0.02). TERT promoter hotspot mutations were not present and TERT copy number gain was only observed in 3/70 tumour samples. TERT or chromosome 18 copy number alterations were not associated with telomerase expression and activity or TL. However, hypermethylation of TERT promoter in Region B - in the proximity of the transcription start site - was inversely correlated with TERT expression and telomerase activity and positively correlated with TL. Global LINE1 methylation was positively correlated with TERT promoter Region B methylation and was inversely correlated with telomerase activity, TERT expression and the upstream Region A methylation. The results show that telomerase activation, TERT expression and shorter telomeres are commonly found in SI-NETs. Aberrant DNA methylation of TERT promoter and of LINE1 can be implicated in abnormal regulation of TERT in SI-NETs.

Entities:  

Keywords:  DNA methylation; SI-NET; TERT; Telomere; telomerase

Mesh:

Substances:

Year:  2019        PMID: 31322481      PMCID: PMC6791720          DOI: 10.1080/15592294.2019.1634987

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  30 in total

1.  Telomere measurement by quantitative PCR.

Authors:  Richard M Cawthon
Journal:  Nucleic Acids Res       Date:  2002-05-15       Impact factor: 16.971

Review 2.  The RNA polymerase II core promoter: a key component in the regulation of gene expression.

Authors:  Jennifer E F Butler; James T Kadonaga
Journal:  Genes Dev       Date:  2002-10-15       Impact factor: 11.361

3.  Telomerase activity in neuroendocrine tumors.

Authors:  M Bockhorn; A Frilling; U Clauer; M Hertl; C E Broelsch
Journal:  Int J Surg Investig       Date:  2000

4.  hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site.

Authors:  Rebekah L Zinn; Kevin Pruitt; Sayaka Eguchi; Stephen B Baylin; James G Herman
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

5.  DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Authors:  Yuchen Jiao; Chanjuan Shi; Barish H Edil; Roeland F de Wilde; David S Klimstra; Anirban Maitra; Richard D Schulick; Laura H Tang; Christopher L Wolfgang; Michael A Choti; Victor E Velculescu; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos
Journal:  Science       Date:  2011-01-20       Impact factor: 47.728

Review 6.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

7.  Progressive epigenetic dysregulation in neuroendocrine tumour liver metastases.

Authors:  Anna Karpathakis; Harpreet Dibra; Christodoulos Pipinikas; Andrew Feber; Tiffany Morris; Joshua Francis; Dahmane Oukrif; Dalvinder Mandair; Marinos Pericleous; Mullan Mohmaduvesh; Stefano Serra; Olagunju Ogunbiyi; Marco Novelli; TuVinh Luong; Sylvia L Asa; Matthew Kulke; Christos Toumpanakis; Tim Meyer; Martyn Caplin; Stephan Beck; Christina Thirlwell
Journal:  Endocr Relat Cancer       Date:  2017-01-03       Impact factor: 5.678

8.  Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene.

Authors:  S Renaud; D Loukinov; Z Abdullaev; I Guilleret; F T Bosman; V Lobanenkov; J Benhattar
Journal:  Nucleic Acids Res       Date:  2007-01-31       Impact factor: 16.971

9.  TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes.

Authors:  João Vinagre; Joana Nabais; Jorge Pinheiro; Rui Batista; Rui Caetano Oliveira; António Pedro Gonçalves; Ana Pestana; Marta Reis; Bárbara Mesquita; Vasco Pinto; Joana Lyra; Maria Augusta Cipriano; Miguel Godinho Ferreira; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares
Journal:  Sci Rep       Date:  2016-07-14       Impact factor: 4.379

10.  Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma.

Authors:  Na Wang; Hanna Kjellin; Anastasios Sofiadis; Omid Fotouhi; C Christofer Juhlin; Martin Bäckdahl; Jan Zedenius; Dawei Xu; Janne Lehtiö; Catharina Larsson
Journal:  Oncotarget       Date:  2016-04-19
View more
  1 in total

1.  The expression level of chicken telomerase reverse transcriptase in tumors induced by ALV-J is positively correlated with methylation and mutation of its promoter region.

Authors:  Yong Xiang; Qinxi Chen; Qingbo Li; Canxin Liang; Weisheng Cao
Journal:  Vet Res       Date:  2022-06-23       Impact factor: 3.829

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.